Overview
Cartesian Therapeutics, Inc., based in the United States, operates primarily in the biotechnology sector, focusing on the development of innovative therapeutics. The company stands out for its pioneering work in engineered cell therapies targeting autoimmune diseases, cancer, and respiratory conditions. A significant aspect of Cartesian Therapeutics' approach involves utilizing mRNA technology to modify cells, aiming for more controlled and robust treatment responses. Among its key projects are targeted therapies for myasthenia gravis and acute respiratory distress syndrome, reflecting its commitment to addressing complex medical challenges. The firm leverages cutting-edge scientific methodologies to advance its pipeline, demonstrating a strong commitment to revolutionizing the treatment landscape through biotechnological breakthroughs.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Cartesian Therapeutics, Inc. as of June 30, 2025 is 1.03 MM.
- The operating income for Cartesian Therapeutics, Inc. as of June 30, 2025 is -80.43 MM.
- The net income for Cartesian Therapeutics, Inc. as of June 30, 2025 is -36.26 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 1.03 | -80.43 | -36.26 |
| 2025-03-31 | 34.17 | -44.86 | -38.31 |
| 2024-12-31 | 38.91 | -35.52 | -77.42 |
| 2024-09-30 | 47.94 | -40.69 | -244.83 |
| 2024-06-30 | 54.10 | -36.18 | -229.65 |
| 2024-03-31 | 25.91 | -68.57 | -254.87 |
| 2023-12-31 | 26.00 | -74.41 | -219.71 |
| 2023-09-30 | 127.48 | -30.24 | -1.49 |
| 2022-12-31 | 110.78 | 14.54 | 35.38 |
| 2021-12-31 | 85.08 | -4.60 | -25.69 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | -1.71 | -1.73 |
| 2024-12-31 | -4.48 | -4.49 |
| 2024-09-30 | -23.44 | -23.44 |
| 2024-06-30 | -33.31 | -33.32 |
| 2024-03-31 | -55.74 | -55.75 |
| 2023-12-31 | -49.76 | -49.76 |
| 2023-09-30 | ||
| 2022-12-31 | 7.33 | 2.98 |
| 2021-12-31 | -6.74 | -6.60 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Cartesian Therapeutics, Inc. as of June 30, 2025 is -33.94 MM.
- The cash from investing activities for Cartesian Therapeutics, Inc. as of June 30, 2025 is -10.22 MM.
- The cash from financing activities for Cartesian Therapeutics, Inc. as of June 30, 2025 is 117.31 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -33.94 | -10.22 | 117.31 |
| 2025-03-31 | -30.86 | -9.21 | 117.37 |
| 2024-12-31 | -23.67 | -8.74 | 168.43 |
| 2024-09-30 | -39.96 | -1.89 | 181.73 |
| 2024-06-30 | -62.86 | 4.31 | 32.44 |
| 2024-03-31 | -58.31 | 5.88 | 29.74 |
| 2023-12-31 | -51.16 | 34.61 | -13.14 |
| 2023-09-30 | -57.65 | 13.26 | 11.99 |
| 2022-12-31 | -31.63 | -15.00 | 39.22 |
| 2021-12-31 | -60.38 | -17.14 | 52.90 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Cartesian Therapeutics, Inc. as of June 30, 2025 is -7.03.
- The p/book for Cartesian Therapeutics, Inc. as of June 30, 2025 is -12.37.
- The p/tbv for Cartesian Therapeutics, Inc. as of June 30, 2025 is -1.22.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -7.03 | -12.37 | -1.22 |
| 2025-03-31 | -55.38 | -1.83 | |
| 2024-12-31 | -1.97 | 641.76 | -2.44 |
| 2024-09-30 | -1.77 | -4.00 | -1.35 |
| 2024-06-30 | -1.99 | -4.35 | -1.61 |
| 2024-03-31 | -0.77 | -0.32 | |
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2022-12-31 | |||
| 2021-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Cartesian Therapeutics, Inc. as of June 30, 2025 is -0.43.
- The ebit (3y)/ev for Cartesian Therapeutics, Inc. as of June 30, 2025 is -1.21.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.43 | -1.21 |
| 2025-03-31 | -0.47 | -0.74 |
| 2024-12-31 | -1.00 | -0.64 |
| 2024-09-30 | -0.78 | -0.23 |
| 2024-06-30 | -0.39 | -0.13 |
| 2024-03-31 | -0.72 | -0.25 |
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2022-12-31 | ||
| 2021-12-31 |
Management Effectiveness
- The roa for Cartesian Therapeutics, Inc. as of June 30, 2025 is -0.11.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.11 | ||||
| 2025-03-31 | -0.24 | -10.78 | 18.93 | -3.30 | |
| 2024-12-31 | -0.80 | -15.89 | 9.08 | -2.59 | |
| 2024-09-30 | -24.66 | -36.96 | |||
| 2024-06-30 | -17.44 | -2.72 | |||
| 2024-03-31 | -15.04 | -18.17 | |||
| 2023-12-31 | |||||
| 2023-09-30 | |||||
| 2022-12-31 | |||||
| 2021-12-31 | -0.16 | -0.76 | -0.73 | -1.04 |
Gross Margins
- The gross margin for Cartesian Therapeutics, Inc. as of June 30, 2025 is -0.46.
- The net margin for Cartesian Therapeutics, Inc. as of June 30, 2025 is -1.12.
- The operating margin for Cartesian Therapeutics, Inc. as of June 30, 2025 is -1.29.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | -0.46 | -1.12 | -1.29 |
| 2025-03-31 | -0.16 | -1.99 | -0.93 |
| 2024-12-31 | -0.04 | -5.11 | -0.85 |
| 2024-09-30 | 0.05 | -4.24 | -0.67 |
| 2024-06-30 | -1.18 | -9.84 | -2.67 |
| 2024-03-31 | -1.76 | -8.45 | -3.32 |
| 2023-12-31 | |||
| 2023-09-30 | -3.72 | -4.45 | -4.58 |
| 2022-12-31 | |||
| 2021-12-31 | -0.82 | -7.70 | -1.13 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1453687 |
Industry Groups
| SIC 2834 - Pharmaceutical Preparations |
